ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / RLMD / options
RZLT (37) AVTX (17) CAPR (34) ALT (21) ⌘ Pro Terminal →

Relmada Therapeutics Inc. (RLMD) Options Positioning, Max Pain & Unusual Sweeps

$3.84 +7.26% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.88

Relmada Therapeutics Inc. (RLMD) carries a Roarable Rating of E (Strong Sell) with 30/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $381.9M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on RLMD Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is RLMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Relmada Therapeutics Inc. (NASDAQ: RLMD) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $3.84 (+7.26% 1D, market cap $381.9M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Active quantitative signal LIQUIDITY_TAILWIND (BULLISH, conviction undefined/100) notes: undefined.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does RLMD compare to RZLT and AVTX in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RLMD carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, RZLT (Rezolute Inc. (NV)) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $382.1M) and AVTX (Avalo Therapeutics Inc.) posts a E grade (17/100 RQD, P/E N/A, ROIC -35.0%, cap $384.5M). Among the 5-stock peer group, RLMD leads on earnings multiple (N/A) while ALT leads on capital efficiency (-34.7% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for RLMD?
▼

Per RLMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001553643), Relmada Therapeutics Inc. generated $165.5M in revenue (-29.6% YoY), $0 in net income, and -$45.8M in free cash flow against $94.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $3.88 (+1.12%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (30/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.6% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510030
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Cash (6)Whales (5)SEC (10)Macro (6)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-12.5% Base Target
$8 Bull$3 Base$3 Bear
📬 FREE RLMD RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for RLMD)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (30/100 Composite)
🔍 WHY RLMD SCORES 30/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (33% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9

▲ #2 Bullish Driver: Cash Engine Quality+6/20 pts (20% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
22
Grade E$3.36+0% Next Q
Q2 (-2Q)
25
Grade E$3.36-4.5% Next Q
Q3 (-1Q)
27
Grade E$3.21+19.6% Next Q
Current
30
Grade E$3.84-9.6% Hist 90D α
Trajectory: E (22) → E (30)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a RLMD Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While RLMD currently carries a cautious 30/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.80) and Max Pain ($4.03) forces dealer call-delta covering toward $8.40.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $RLMD• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “RLMD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 30%NO 70%Trade / Inspect Odds →
CALL VS. PUT WHALE SHARE
— (No Active Options Snapshot)
Put/Call Ratio: — (No Active Options Snapshot)
MAX-PAIN EXPIRATION MAGNET
— (No Active Options Snapshot)
No active options chain max-pain snapshot on file
HISTORICAL 20D VOLATILITY SWING
±12.5%
Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (RLMD)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for RLMD.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring RLMD)

  • ✓Walkthrough of RLMD's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
RLMD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -48.18%▲ RESISTANCE BREAKOUT
2026-11-03O $3.44H $3.84L $3.44C $3.84VOL 1.41M
RES: $3.29SUP: $2.58SMA50: $3.80SMA200: $5.35
$8.35$6.92$5.49$4.06$2.63RES $3.29SUP $2.58$3.842026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

RLMD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 RLMD Butterfly Map → + Track RLMD →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -29.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on RLMD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for RLMD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for RLMD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (RLMD)

Health Care Rank #794 of 1015 ⚔️ RZLT vs RLMD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (RLMD vs. RZLT, AVTX, CAPR, ALT)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Relmada Therapeutics Inc. (RLMD) ranks #794 by composite RQD confidence (30/100, grade E) and #481 by equity capitalization ($381.9M). Within this direct 5-issuer industry benchmark cohort, RLMD leads on earnings valuation at N/A trailing P/E, while ALT leads on capital efficiency and profitability with -34.7% ROIC and — gross margin. RZLT currently holds the highest overall quantitative score in the immediate peer group at 37/100 (D-) compared with RLMD at 30/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
RLMD ACTIVE
Relmada Therapeutics Inc.
E 30/100 — — -35.0% +7.26% $381.9M Benchmark Subject
RZLT
Rezolute Inc. (NV)
D- 37/100 — — -35.0% -1.77% $382.1M /rzlt-vs-rlmd →
AVTX
Avalo Therapeutics Inc.
E 17/100 — — -35.0% +2.09% $384.5M /avtx-vs-rlmd →
CAPR
Capricor Therapeutics Inc.
E 34/100 — — -35.0% +13.48% $370.9M /capr-vs-rlmd →
ALT
Altimmune Inc.
E 21/100 — — -34.7% -0.98% $396.8M /alt-vs-rlmd →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2024–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001553643 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Relmada Therapeutics Inc. (RLMD) reported GAAP revenue of $165.5M (-29.6% vs. FY2024 revenue of $234.9M ) , GAAP net income of $0, operating cash flow of -$45.8M, and free cash flow of -$45.8M (+11.5% YoY). On the balance sheet, RLMD closed FY2025 with $94.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $165.5M $0 -$45.8M -$45.8M $94.0M —
FY2024 (FY) 2024-12-31 $234.9M $0 -$51.8M -$51.8M $45.8M —

3. RLMD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is RLMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Relmada Therapeutics Inc. (NASDAQ: RLMD) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $3.84 (+7.26% 1D, market cap $381.9M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Active quantitative signal LIQUIDITY_TAILWIND (BULLISH, conviction undefined/100) notes: undefined.

How does RLMD compare to RZLT and AVTX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RLMD carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, RZLT (Rezolute Inc. (NV)) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $382.1M) and AVTX (Avalo Therapeutics Inc.) posts a E grade (17/100 RQD, P/E N/A, ROIC -35.0%, cap $384.5M). Among the 5-stock peer group, RLMD leads on earnings multiple (N/A) while ALT leads on capital efficiency (-34.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for RLMD?

Per RLMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001553643), Relmada Therapeutics Inc. generated $165.5M in revenue (-29.6% YoY), $0 in net income, and -$45.8M in free cash flow against $94.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is RLMD trading relative to its 50-day, 200-day, and 52-week technical levels?

RLMD last traded at $3.84 (+7.26% on volume of 2,257,005 shares), positioning the stock +1.05% above its 50-day simple moving average ($3.80) and -28.22% below its 200-day simple moving average ($5.35). Across its 52-week range of $2.15 to $8.00, RLMD sits at the 28.9% percentile with a 14-day RSI of 52.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.36 to $4.32).

Direct Sub-Reports: RLMD RQD Cockpit RLMD 12M Forecast RLMD Earnings & Move RLMD Dividends & DRIP RLMD Insiders & 13F RLMD Whale Options RLMD Profit Sankey RLMD News & Why
ROARABLE RATING BRIEF • RQD 30/100 (E) ✓ SEC XBRL & RQD VERIFIED

RLMD — Relmada Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Relmada Therapeutics Inc. (RLMD) earns a live Roarable RQD composite score of 30/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $3.84 (+7.26% 1D, market capitalization $381.9M).

  • Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of -12.48%.
  • Whale 13F & Options Flow (5/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (6/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 1/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Relmada Therapeutics Inc. Is a NASDAQ-listed issuer classified in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry..4B. Reported revenue is — for both FY 2025 and FY 2024 in the SEC financials, indicating no revenue recognition in the reported periods.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Relmada Therapeutics Inc. (RLMD) reported $165.5M in annual revenue (up from $234.9M in FY2024, -29.6% YoY) and $0 in GAAP net income. Over the multi-year SEC filing window from FY2024 ($234.9M revenue, $0 net income) through FY2025, RLMD scaled operating cash flow to -$45.8M and free cash flow to -$45.8M, backed by $94.0M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 30/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -12.48% and institutional whale pillar of 5/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 5/20, sustained execution supports upside toward the upper end of the $2.15 – $8.00 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The only cross-market linkage is the macro liquidity signal, which implies the stock's sensitivity to broad liquidity conditions rather than to any specific supplier or customer. Because the graph shows a high beta elasticity to net liquidity, a prospective investor should note that liquidity-driven moves could amplify price changes in either direction.

  • Key Question #1: Can RLMD sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $165.5M and free cash flow of -$45.8M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is RLMD's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

RLMD Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Relmada Therapeutics Inc. (RLMD) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to RLMD Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

RLMD Bull vs. Bear Conversation Board — What's Your Call at $3.84?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON RLMD 🐻 33% BEARISH CONVICTION
1. Pick Your Side on RLMD:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
CA CashFlowKing RQD DEBATE OPENER • FCF Compounder Hunter 🐂 BULLISH 🎯 Target: $4.58 (+27.9%)
📌 Pinned Debate

The Butterfly Supply-Chain Graph's LIQUIDITY_TAILWIND signal scores 96/100 and is marked BULLISH, indicating a macro backdrop that favo

Picked up a starter position in RLMD in my $100K Virtual Cash book at $3.58. The Butterfly Supply-Chain Graph's LIQUIDITY_TAILWIND signal scores 96/100 and is marked BULLISH, indicating a macro backdrop that favors the stock despite falling net liquidity.. Trading inside a $2.15–$8.00 52-week range with -12.48% FCF yield gives solid downside support if Biotechnology: Pharmaceutical Preparations multiples expand this quarter.

EarningsSniper 🐂 BULL

Both sides have a point here — RLMD's 10/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

FA FadeTheHype RQD DEBATE OPENER • Contrarian Tape Reader 🐻 BEARISH 🎯 Target: $2.79 (-22.1%)
Spot @ $3.58

Negative free cash flow of -$45.8M against only $3.5M in cash, a Piotroski F-Score of 1/9, and an RQD grade of E all point to significa

Here is the bear case nobody on the bull side wants to address on RLMD: Negative free cash flow of -$45.8M against only $3.5M in cash, a Piotroski F-Score of 1/9, and an RQD grade of E all point to significant forensic and funding risk.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%